Researchers in Australia say they have identified a molecular mechanism that appears to drive the spread of triple‑negative breast cancer (TNBC), and shown in preclinical models that reversing that mechanism can limit metastasis. The work raises the prospect that an existing drug class could be repurposed to treat a subset of patients with one of the most lethal breast cancer subtypes.
What the researchers found
Teams from the University of Adelaide and the Olivia Newton‑John Cancer Research Institute report that levels of a small, naturally occurring molecule called miR‑342 are linked to disease behaviour in TNBC. Tumours with reduced miR‑342 expression were associated with activation of a cancer‑promoting pathway referred to as E2F, and with an increased tendency to metastasize.
In laboratory models, restoring miR‑342 cut the ability of cancer cells to spread to distant organs such as the lungs and bones. The investigators also tested an available breast cancer drug, palbociclib — a CDK4/6 inhibitor currently approved for certain hormone receptor‑positive cancers — and observed that it substantially slowed growth of metastatic tumours in models characterised by low miR‑342.
"Most deaths from breast cancer occur because the cancer spreads to other parts of the body, rather than being caused by the primary tumor itself,"
The study, published in EMBO Molecular Medicine, suggests two interrelated clinical possibilities: first, that measuring miR‑342 in tumours could help identify patients with TNBC who carry a higher metastatic risk; second, that some of those patients might respond to therapies that inhibit CDK4/6.
Why this matters
Triple‑negative breast cancer lacks the hormone receptors and HER2 protein that guide many effective targeted treatments, which makes it one of the more difficult breast cancer subtypes to treat. Metastasis — the spread of cancer cells beyond the primary tumour — is the principal cause of death from breast cancer.
By pinpointing a molecular switch tied to metastatic behaviour and showing that existing agents can counteract its effects in preclinical systems, the study opens a pathway toward more personalised therapy for a subgroup of TNBC patients.
Key elements of the research
- miR‑342: a naturally occurring microRNA whose low levels correlated with metastatic disease in the study.
- E2F pathway: a cancer‑driving signalling route that was more active when miR‑342 was reduced.
- Palbociclib (CDK4/6 inhibitor): an existing drug that reduced metastatic tumour growth in models with low miR‑342.
The investigators propose that miR‑342 assessment could serve as a biomarker to select patients for CDK4/6 inhibitor therapy, repurposing a drug already in clinical use for another breast cancer subtype.
| Feature | Low miR‑342 | Restored miR‑342 / CDK4/6 inhibition |
|---|---|---|
| Associated pathway activity | High E2F activity | Reduced metastatic activity observed |
| Metastatic behaviour (preclinical) | Increased spread to lungs and bones | Marked reduction in spread and growth |
Next steps and limitations
These findings are derived from preclinical models and molecular analyses; they do not yet constitute evidence that the approach will be effective in patients. Clinical trials will be needed to determine whether measuring miR‑342 can reliably identify TNBC patients who benefit from CDK4/6 inhibitors, and to quantify the benefit and risks of such treatment in that population.
The study nonetheless points to a tractable biomarker and a potential therapeutic strategy that could be evaluated in clinical settings, speeding the translation from laboratory insight to patient care because palbociclib is already approved for other indications.
If validated, the approach could help personalise treatment for a disease subtype that currently has fewer targeted options, and address the primary driver of breast cancer mortality: metastatic spread.
